Syncom Formulation (India) Share PriceSyncom Formulation (India)

₹9.42
1.03 (12.28%)
As on 04 October, 2023 | 05:41 BSE: 524470 NSE: SYNCOMFISIN: INE312C01025

Syncom Formulation (India) Performance

Day Range

  • Low 8.45
  • High 9.7
9.42

52 Week Range

  • Low 4.6
  • High 11.6
9.42
  • Open Price8.55
  • Previous Close8.4
  • Volume16724057

Start SIP in Syncom Formulation (India)

Start SIP

Syncom Formulation (India) Share Price

  • Over 1 Month 9.03%
  • Over 3 Month 25.27%
  • Over 6 Month 58.05%
  • Over 1 Year 16.58%

Syncom Formulation (India) Key Statistics

P/E Ratio 43
PEG Ratio 3.3
Market Cap Cr 886
Price to Book Ratio 3.5
EPS 0.2
Dividend 0
Relative Strength Index 68.43
Money Flow Index 53.29
MACD Signal 0.03
Average True Range 0.38

Syncom Formulation (India) Investment Rating

  • Master Rating:
  • Syncom Formulations India has an operating revenue of Rs. 232.69 Cr. on a trailing 12-month basis. An annual revenue growth of 3% is not great, Pre-tax margin of 12% is healthy, ROE of 7% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 12% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 4% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 83 which is a GOOD score indicating consistency in earnings, a RS Rating of 65 which is FAIR indicating the recent price performance, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 114 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has remained stable in the last reported quarter. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Syncom Formulation (India) Financials
IndicatorJun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 596157545158
Operating Expenses Qtr Cr 535551504856
Operating Profit Qtr Cr 666432
Depreciation Qtr Cr 111111
Interest Qtr Cr 111111
Tax Qtr Cr 222211
Net Profit Qtr Cr 484445
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 239232
Operating Expenses Annual Cr 205200
Operating Profit Annual in Cr 2019
Depreciation Cr 54
Interest Annual Cr 31
Tax Annual Cr 66
Net Profit Annual Cr 2020
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 16
Cash from Investing Activity Annual Cr -27
Cash from Financing Annual Activity Cr 8
Net Cash Flow Annual Cr -2
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 256222
Fixed Assets Annual Cr 116100
Total Non Current Assets Annual Cr 196168
Total Current Assets Annual Cr 181140
Total Assets Annual Cr 377308
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 33
ROE Annual % 89
ROCE Annual % 1112
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 1514
IndicatorJun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 606157545158
Operating Expenses Qtr Cr 535551504856
Operating Profit Qtr Cr 666432
Depreciation Qtr Cr 111111
Interest Qtr Cr 111111
Tax Qtr Cr 222211
Net Profit Qtr Cr 484445
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 239
Operating Expenses Annual Cr 205
Operating Profit Annual in Cr 20
Depreciation Cr 5
Interest Annual Cr 3
Tax Annual Cr 7
Net Profit Annual Cr 20
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr
Cash from Investing Activity Annual Cr
Cash from Financing Annual Activity Cr
Net Cash Flow Annual Cr
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 256
Fixed Assets Annual Cr 116
Total Non Current Assets Annual Cr 196
Total Current Assets Annual Cr 182
Total Assets Annual Cr 378
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 3
ROE Annual % 8
ROCE Annual % 11
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 15

Syncom Formulation (India) Technicals

EMA & SMA

Current Price
₹9.42
1.03 (12.28%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • ₹8.63
  • 50 Day
  • ₹8.41
  • 100 Day
  • ₹8.05
  • 200 Day
  • ₹7.88
  • 20 Day
  • ₹8.63
  • 50 Day
  • ₹8.5
  • 100 Day
  • ₹7.87
  • 200 Day
  • ₹7.5

Syncom Formulation (India) Resistance and Support

PIVOT
₹9.2
Resistance
First Resistance ₹9.91
Second Resistance ₹10.4
Third Resistance ₹11.11
RSI 68.44
MFI 53.29
MACD Single Line 0.03
MACD 0.06
Support
First Resistance ₹8.71
Second Resistance ₹8
Third Resistance ₹7.51

Syncom Formulation (India) Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 19,683,204 1,062,302,520 53.97
Week 6,400,336 345,106,090 53.92
1 Month 3,103,826 183,994,820 59.28
6 Month 3,191,612 180,836,740 56.66

Syncom Formulation (India) Result Highlights

Syncom Formulation (India) Synopsis

NSE-Medical-Diversified

Syncom Formul. is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 224.64 Cr. and Equity Capital is Rs. 94.00 Cr. for the Year ended 31/03/2023. Syncom Formulation (India) Ltd. is a Public Limited Listed company incorporated on 21/06/1988 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1988PLC047759 and registration number is 047759.
Market Cap 888
Sales 233
Shares in Float 46.06
No of funds 1
Yield 1.01
Book Value 3.47
U/D Vol ratio 1
LTDebt / Equity
Alpha 0.12
Beta 0.46

Syncom Formulation (India)

Owner NameJun-23Mar-23Dec-22
Promoters 50.57%50.57%50.57%
Mutual Funds
Foreign Portfolio Investors
Individual Investors 45%44.85%45.02%
Others 4.43%4.58%4.41%

Syncom Formulation (India) Management

Name Designation
Mr. Kedarmal Shankarlal Bankda Executive Chairman
Mr. Vijay Shankarlal Bankda Managing Director
Mrs. Rinki Ankit Bankda Whole Time Director
Mr. Krishna Das Neema Independent Director
Mr. Praveen Jindal Independent Director
Mr. Vinod Kumar Kabra Independent Director
Mrs. Ruchi Jindal Addnl. Independent Woman Director

Syncom Formulation (India) Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Syncom Formulation (India) Corporate Action

Date Purpose Remarks
2023-08-14 Quarterly Results
2023-05-29 Audited Results
2023-02-13 Quarterly Results
2022-11-14 Quarterly Results
2022-08-13 Quarterly Results & Final Dividend

Syncom Formulation (India) MF Shareholding

Name Amount(cr)
Motilal Oswal S&P BSE Healthcare ETF 8
  • Company Name
  • CMP
  • Chg(%)
  • Company Name
  • CMP
  • Chg(%)

Syncom Formulation (India) FAQs

What is Share Price of Syncom Formulation (India) ?

Syncom Formulation (India) share price is ₹9 As on 04 October, 2023 | 05:27

What is the Market Cap of Syncom Formulation (India) ?

The Market Cap of Syncom Formulation (India) is ₹885.5 Cr As on 04 October, 2023 | 05:27

What is the P/E ratio of Syncom Formulation (India) ?

The P/E ratio of Syncom Formulation (India) is 43 As on 04 October, 2023 | 05:27

What is the PB ratio of Syncom Formulation (India) ?

The PB ratio of Syncom Formulation (India) is 3.5 As on 04 October, 2023 | 05:27

Q2FY23